All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 16, 2022
Home » Topics » Financings, BioWorld Asia

Financings, BioWorld Asia
Financings, BioWorld Asia RSS Feed RSS

Financings for May 10, 2022

May 10, 2022
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: Intrinsic Medicine, Inxmed.
Read More
Antibodies attacking cancer cell

Askgene’s series A adds $20M for cytokine fusion, antibody pipeline

May 10, 2022
By Jennifer Boggs
No Comments
Askgene Pharma Inc., which less than two weeks ago reported positive initial data from an ongoing phase I/II trial testing its claudin 18.2-targeting candidate, ASKB-589, added $20 million in a series A round, intended to advance the company’s clinical pipeline and support further development of its Smartkine cytokine drug platform.
Read More
IPO money

Pepgen and B&L join a struggling IPO market

May 10, 2022
By Lee Landenberger
No Comments
IPOs continue to be sluggish but two companies, Pepgen Inc. and Bausch & Lomb Corp., that began trading May 6 managed to sidestep the turbulence despite having to lower their expectations before the market opened.
Read More
Gold dollar sign

Ashvattha lands $69M series B, Huadong licensing deal

May 3, 2022
By David Ho
No Comments
Ashvattha Therapeutics Inc. secured $69 million in a series B financing that it said will strengthen its ability to develop hydroxyl dendrimer-based medicines and accelerate efforts to advance its candidates to the clinic.
Read More

Financings for May 3, 2022

May 3, 2022
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: RVAC Medicines, Valneva.
Read More

Financings for April 26, 2022

April 26, 2022
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: Biotech Group Acquisition, Hillevax, Oncoquest, Quest Pharmatech, Takeda.
Read More

Financings for April 12, 2022

April 12, 2022
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: Rona.
Read More
European flag, vial, syringe

NEC Oncoimmunity bags $4.8M to develop vaccines for SARS-CoV-2 variants, other betacoronaviruses

April 12, 2022
By Gina Lee
No Comments
NEC Corp. subsidiary NEC Oncoimmunity AS recently received $4.8 million from the Coalition for Epidemic Preparedness Innovations to fund the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses.
Read More

Biopharma financings in Q1 at lowest point since 2017

April 12, 2022
By Karen Carey
No Comments
Biopharma financings for the first quarter of 2022 are at a five-year low, with 65.8% less money and 53% fewer transactions than a year ago. The industry raised $13.1 billion through 249 financings, compared with $38.3 billion from 529 transactions in 2021.
Read More

Financings for April 5, 2022

April 5, 2022
No Comments
Biopharmas in Asia-Pacific raising money in public or private financings: Cellorigin, Jiangsu Nhwa, Seax Ventures, Trevena.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 32 33 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 16, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 16.
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing